Currently, there are only two studies about RSV in bladder cancer models(transitional cell carcinoma) in vivo (Table 2 and Figure 2).Bai et al. (2010) used axenograft model of bladder cancer to investigate RSV effects invivo. The authors found that RSV treatment significantly slowed thegrowth of tumors and it was associated with expression decrease of thepro-angiogenic regulators VEGF and FGF-2. The gene discussed is FGF2; the disease is urinary bladder cancer.